Clinical trials: Relapsed /Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia
Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of liposome-encapsulated daunorubicin-cytarabine when given with fludarabine phosphate, cytarabine, and filgrastim and to see how well they work in treating younger…
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Trial name
- NCT02642965
- Testing
- Cytarabine, Filgrastim, Fludarabine Phosphate
- Where
- 73 sites in United States, Canada
- Volunteers
- 38 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
This phase II trial studies how well olaparib works in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory), or myelodysplastic syndrome.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT03953898
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Olaparib
- Where
- 11 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Acute Leukemias
Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia
The study will evaluate the efficacy, safety and tolerability of two dosing schedules of LDE225 in patients with relapsed/refractory acute leukemia or elderly patients with untreated acute leukemia.
- Trial name
- NCT01826214
- Testing
- LDE225
- Where
- 23 sites in United States, Australia and 9 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
This phase II trial studies the side effects and the best dose of alemtuzumab when given together with fludarabine phosphate and low-dose total body irradiation (TBI) and how well it works before donor stem cell transplant in…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00040846
- Testing
- alemtuzumab, fludarabine phosphate, total-body irradiation
- Where
- 7 sites in United States, Italy
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy, such as cytarabine and clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01656031
- Testing
- clofarabine, cytarabine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Wake Forest University Health Sciences
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
This phase Ib/II trial studies the best dose and side effects of avelumab when given together with azacitidine and to see how well they work in treating patients with acute myeloid leukemia that is not responding to treatment or…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT02953561
- Testing
- Avelumab, Azacitidine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims of the study are to learn how safe GDX012 is, how treatment with GDX012 is tolerated and…
- Trial name
- NCT05886491
- Testing
- GDX012, Chemotherapy Agents
- Where
- 11 sites in United States, Japan
- Volunteers
- 16 people
- Sponsor
- Takeda
Myeloid Leukemia
Study of IMC-EB10 in Participant With Leukemia
The purpose of this study is to determine if IMC-EB10 is safe for participants with leukemia, and also to determine the best dose of IMC-EB10 to give to participants.
- Trial name
- NCT00887926
- Testing
- IMC-EB10
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Acute Myeloid Leukemia
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
This study includes patients with relapsed acute leukemia who have previously been treated with standard treatment that is still present and there is no curative treatment option available.
- Trial name
- NCT03374332
- Testing
- Gemtuzumab Ozogamicin (GO), Donor Leukocytes
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Brown University
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of milademetan tosylate and to see how well it works with cytarabine with or without ventoclax in treating participants with acute myeloid leukemia that has come back…
- Conditions
- Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT03634228
- Testing
- Cytarabine, Milademetan Tosylate, Venetoclax
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
This phase I/II trial studies the side effects and best dose of mitoxantrone hydrochloride when given together with filgrastim, cladribine, and cytarabine and to see how well they work in treating patients with acute myeloid…
- Conditions
- Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia
- Trial name
- NCT02044796
- Testing
- Cladribine, Cytarabine, Filgrastim
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Myeloid, Acute
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
This study is designed to test the combination of Plerixafor with G-CSF for chemosensitization in patients with relapsed or refractory AML.
- Trial name
- NCT00906945
- Testing
- G-CSF, Plerixafor, Mitoxantrone
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia, Higher Risk Myelodysplastic Syndrome
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
This is a phase II trial of nivolumab and low dose cyclophosphamide (CTX) when given in combination to patients with relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS) who are not…
- Trial name
- NCT03417154
- Testing
- Nivolumab, Low dose Cyclophosphamide (CTX) Daily, Low dose Cyclophosphamide (CTX) Every 7 Days
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia
Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- AML1107 (NCT00775593)
- Testing
- clofarabine, temsirolimus
- Where
- 19 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The objective of this study was to assess the safety and tolerability, including the maximum tolerated dose, of gilteritinib in participants with relapsed or treatment-refractory acute myeloid leukemia (AML).
- Trial name
- NCT02014558
- Testing
- Gilteritinib, Voriconazole, Midazolam
- Where
- 26 sites in United States, Germany and 1 more
- Volunteers
- 265 people
- Sponsor
- Astellas Pharma Global Development, Inc.
AML
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
This research study is evaluating how a drug called lenalidomide, given in combination with the standard chemotherapy regimen of Mitoxantrone, Etoposide, and Cytarabine, commonly referred to as MEC, works in individuals with…
- Trial name
- NCT03118466
- Testing
- Etoposide, Cytarabine, Lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Massachusetts General Hospital
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00818961
- Testing
- alemtuzumab, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northside Hospital, Inc.
Acute Myelogenous Leukemia
MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
A phase II trial of CD3/CD19 depleted, IL-15 activated, donor natural killer (NK) cells in adults and subcutaneous IL-15 given after a preparative regimen for the treatment of relapsed or refractory acute myelogenous leukemia…
- Trial name
- NCT02395822
- Testing
- IL-15
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
This phase I/II trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia.
- Conditions
- Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm
- Trial name
- NCT01445080
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate
- Where
- 25 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)